Cargando…

An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL

We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be conf...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakadia, Purvi M., Schmidmaier, Ralf, Völkl, Andreas, Schneider, Irene, Huk, Natalia, Schneider, Stephanie, Panzner, Gerda, Neidel, Ulrike, Fritz, Barbara, Spiekermann, Karsten, Bohlander, Stefan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078675/
https://www.ncbi.nlm.nih.gov/pubmed/27812500
http://dx.doi.org/10.1016/j.lrr.2016.09.002
Descripción
Sumario:We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired. Thus, an ETV6/ABL1 fusion positive MPN has the potential to transform very rapidly into ALL.